JP2015527341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527341A5 JP2015527341A5 JP2015525570A JP2015525570A JP2015527341A5 JP 2015527341 A5 JP2015527341 A5 JP 2015527341A5 JP 2015525570 A JP2015525570 A JP 2015525570A JP 2015525570 A JP2015525570 A JP 2015525570A JP 2015527341 A5 JP2015527341 A5 JP 2015527341A5
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- histology
- cetuximab
- determining
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2012/079399 | 2012-07-31 | ||
| CN2012079399 | 2012-07-31 | ||
| PCT/US2013/053091 WO2014028221A1 (en) | 2012-07-31 | 2013-07-31 | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527341A JP2015527341A (ja) | 2015-09-17 |
| JP2015527341A5 true JP2015527341A5 (https=) | 2016-07-07 |
| JP6324381B2 JP6324381B2 (ja) | 2018-05-16 |
Family
ID=50101405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525570A Expired - Fee Related JP6324381B2 (ja) | 2012-07-31 | 2013-07-31 | 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9921222B2 (https=) |
| EP (1) | EP2879712B1 (https=) |
| JP (1) | JP6324381B2 (https=) |
| ES (1) | ES2668861T3 (https=) |
| WO (1) | WO2014028221A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073015B (zh) * | 2014-09-16 | 2020-07-21 | 艾伯维公司 | 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合 |
| CN110520543A (zh) * | 2017-03-29 | 2019-11-29 | 中美冠科生物技术（太仓）有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
| CN112813164A (zh) * | 2021-01-18 | 2021-05-18 | 四川省肿瘤医院 | Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| KR20110008112A (ko) | 1999-08-27 | 2011-01-25 | 제넨테크, 인크. | 항-ＥｒｂＢ2 항체 투여 치료 방법 |
| EP1622941A2 (en) | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| CA2560305C (en) | 2004-03-19 | 2016-07-05 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| CA2612183C (en) | 2005-06-28 | 2015-08-11 | Genentech, Inc. | Egfr and kras mutations |
| DK1951759T3 (da) | 2005-11-12 | 2010-05-10 | Lilly Co Eli | Anti-EGFR-antistoffer |
| WO2008140493A2 (en) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of Californina | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
| US20100009390A1 (en) | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| CN102164960A (zh) | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| WO2010080463A1 (en) | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
| KR101108642B1 (ko) | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| CA2777825A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| BR112012013148A2 (pt) | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| JP2011144124A (ja) | 2010-01-13 | 2011-07-28 | Fujirebio Inc | 活性型ｅｇｆｒ特異抗体 |
| EP2566512A1 (en) | 2010-05-04 | 2013-03-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| JP5965838B2 (ja) | 2010-06-04 | 2016-08-10 | 東亞合成株式会社 | 抗体およびその利用 |
| WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
| EP2603527A1 (en) | 2010-08-10 | 2013-06-19 | Glycotope GmbH | Humanized egfr antibodies |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
-
2013
- 2013-07-31 WO PCT/US2013/053091 patent/WO2014028221A1/en not_active Ceased
- 2013-07-31 US US14/418,684 patent/US9921222B2/en not_active Expired - Fee Related
- 2013-07-31 JP JP2015525570A patent/JP6324381B2/ja not_active Expired - Fee Related
- 2013-07-31 EP EP13829184.4A patent/EP2879712B1/en active Active
- 2013-07-31 ES ES13829184.4T patent/ES2668861T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| Tsimberidou et al. | Precision cancer medicine: the future is now, only better | |
| Tirino et al. | What’s new in gastric cancer: the therapeutic implications of molecular classifications and future perspectives | |
| JP2014514278A5 (https=) | ||
| WO2010145796A3 (en) | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy | |
| Tiseo et al. | Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan | |
| JOP20140128B1 (ar) | تركيبة علاجية تشتمل على مثبط b_raf ومثبط ثان | |
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| JP2017501137A5 (https=) | ||
| JP2015505959A5 (https=) | ||
| Itchins et al. | Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre | |
| Peták et al. | Integrating molecular diagnostics into anticancer drug discovery | |
| JP2016515141A5 (https=) | ||
| JP2016517960A5 (https=) | ||
| WO2014028222A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
| Habib et al. | Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study | |
| JP2015527341A5 (https=) | ||
| JP2013505008A5 (https=) | ||
| Quaquarini et al. | Prognostic and predictive roles of HER2 status in non-breast and non-gastroesophageal carcinomas | |
| Shao et al. | Use and misuse of waterfall plots | |
| Lee et al. | Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer | |
| Nadoshan et al. | Prognostic value of lymph node ratios in node positive rectal cancer treated with preoperative chemoradiation | |
| RU2016102202A (ru) | Биологический маркер опухоли | |
| Hyung et al. | Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis |